Freeline Therapeutics has announced the closing of the previously announced sale of its CMC-focused German subsidiary, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd.
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. The company is dedicated to improving patient lives through innovative, one-time treatments for chronic debilitating diseases.
Read more here.
We make UCL’s research physical and life sciences ideas happen.
